Zhongzhi Pharmaceutical Holdings Limited

Equities

3737

KYG989611085

Pharmaceuticals

Delayed Hong Kong S.E. 04:09:09 2024-04-25 am EDT 5-day change 1st Jan Change
1.22 HKD 0.00% Intraday chart for Zhongzhi Pharmaceutical Holdings Limited -0.81% -14.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhongzhi Pharmaceutical's Attributable Jumps in 2023 MT
Zhongzhi Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 13 June 2024 CI
Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhongzhi Pharmaceutical Expects Over 50% Surge in 2023 Profit MT
Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023 CI
Zhongzhi Pharmaceutical Holdings Limited Approves Interim Dividend CI
Zhongzhi Pharmaceutical’s Profit Up 75% in H1 MT
Zhongzhi Pharmaceutical Holdings Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 2 November 2023 CI
Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhongzhi Pharmaceutical Expects 70% Increase in H1 Profit; Shares Jump 7% MT
Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023 CI
Zhongzhi Pharmaceutical Unit Chooses Builder for New Factory MT
Zhongshan Hengsheng Enters into the Construction Contract with Shenzhen Xinmei CI
Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Special Dividend CI
Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Final Dividend CI
Zhongzhi Pharmaceutical Holdings Limited Proposes Special Dividend for the Year Ended 31 December 2022, Payable on 16 June 2023 CI
Zhongzhi Pharmaceutical Holdings Limited Proposes Payment of Final Dividend for the Year Ended 31 December 2022, Payable on 16 June 2023 CI
Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhongzhi Pharmaceutical Sees Twofold Jump in FY22 Profit MT
Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2022 CI
Zhongzhi Pharmaceutical Clocks Nearly 16% Jump in H1 Profit MT
Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhongzhi Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhongzhi Pharmaceutical Holdings Limited Announces Board Changes CI
Zhongzhi Pharma Forecasts Lower Profit in 2021 MT
Chart Zhongzhi Pharmaceutical Holdings Limited
More charts
Zhongzhi Pharmaceutical Holdings Ltd is a China-based investment holding company. The Company is principally engaged in the research and development, manufacturing and sales of Chinese patent medicines and decoction pieces (consisting of traditional decoction pieces and modern decoction pieces). The Company operates through three segments: pharmaceutical manufacturing segment, operation of chain pharmacies in Zhongshan, Guangdong Province and operation of on-line pharmacies. The Company’s brands include Zeus, Liumian and Caojinghua. The Company mainly conducts its businesses in the domestic market.
More about the company

Annual profits - Rate of surprise